The independent source for health policy research, polling, and news.
1-20 of 51 results
The rapid emergence of the Chinese biotech industry has panicked U.S. politicians, but investors and patients caution that a clampdown on pharmaceutical collaboration could hurt everyone.
The Department of Health and Human Services has launched an effort to streamline clinical research, and legislation is pending in Congress. But patients and providers face participation challenges.
The cuts will shutter two major HIV vaccine research efforts, and a National Institutes of Health senior official said the agency has been instructed not to issue any more HIV vaccine research funding in the next fiscal year, with few exceptions.
The federal government has allocated $1.15 billion to long-covid research without any new treatments yet brought to market. Patients and scientists say it’s time to push harder for breakthroughs.
Though the former president has repeatedly hyped the impact of his experimental drug program, there’s no basis for his claims in government data, and medical experts say he’s exaggerating.
Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
Health plans’ coverage of the medication, branded as Wegovy — which has a $1,300-a-month price tag — is not a sure thing.
When patients with common terminal illnesses such as cancer seek permission for compassionate use of therapies in the testing stage, their requests often are approved. But those with more unusual illnesses say drug companies are rarely willing to provide access.
If you or a loved one has COVID-19, here’s what to consider before seeking experimental treatments.
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
The FDA, under pressure from the Trump administration, has authorized broader use of convalescent plasma for emergency treatment in COVID patients. But several major hospitals are resisting, saying they’ll opt instead to use the scarce resource to complete a clinical trial.
The nation’s top infectious disease official is confident that an independent panel will base vaccine approval on science, not politics.
President Donald Trump touted the Food and Drug Administration’s approval of this unproven COVID-19 treatment for emergency use. That set off reactions ranging from excitement and optimism to scientific concerns and criticism that the decision was politically motivated.
Josie and George Taylor of Everett, Washington, are two of the first people in the U.S. to recover from novel coronavirus infections after joining a clinical trial for the antiviral drug remdesivir.
MDMA, the psychoactive ingredient in the club drug known as molly or ecstasy, is being tested in combination with therapy as a treatment for severe trauma.
California’s stem cell agency, created by a $3 billion bond measure 15 years ago, is almost out of money. Its supporters plan to ask voters for even more funding next year, even though no agency-funded treatments have been approved for widespread use.
© 2026 KFF